Buprenorphine Microdosing Cross Tapers: A Time for Change.

Area of Science:

• Pharmacology
• Addiction Medicine

Background:

• Buprenorphine, a partial opioid agonist, treats chronic pain and opioid use disorder (OUD).
• Current US guidelines mandate 12+ hours of opioid withdrawal before buprenorphine initiation, posing a barrier for patients.
• Buprenorphine-precipitated withdrawal is a significant concern during transitions from full opioid agonists.

Purpose of the Study:

• To evaluate the safety and efficacy of buprenorphine microdosing cross-tapering.
• To advocate for the integration of microdosing strategies into clinical practice and guidelines.
• To identify necessary regulatory and manufacturing changes to support this approach.

Main Methods:

• Review of accumulating evidence on microdose buprenorphine cross-tapering.
• Analysis of current US prescribing guidelines and training protocols.
• Assessment of potential benefits of transdermal and lower-dose sublingual formulations.

Main Results:

• Evidence suggests microdosing buprenorphine is a safe and effective method to transition patients from full opioid agonists.
• This strategy effectively avoids opioid withdrawal and manages pain during the transition.
• The approach is already being utilized across the United States.

Conclusions:

• Buprenorphine microdosing cross-tapering offers a viable solution to overcome barriers in current treatment protocols.
• US prescribing guidelines and training should incorporate this evidence-based approach.
• FDA approval of transdermal formulations and development of lower-dose sublingual options would further facilitate this standard of care.